<ѻý>The Right Ventricle Still Matters in LVAD Patientsѻý> Right heart failure signaled trouble ahead in the Intermacs registry Nov 29, 2021
<ѻý>Hospitalized Acute HF Patients See Clinical Benefits With Empagliflozinѻý> EMPULSE results support early start for the SGLT2 inhibitor, but more data needed, expert says Nov 16, 2021
<ѻý>Peak VO2 Improved After Beta-Blocker Withdrawal in Some HFpEF Patientsѻý> Beta-blockers may not benefit HFpEF patients with chronotropic incompetence Nov 15, 2021
<ѻý>Stem Cells Don't Prevent Acute Heart Failure Eventsѻý> DREAM-HF trial does hold some positive signals, though Nov 15, 2021
<ѻý>Tricuspid Repair Boosts Mitral Valve Surgery Outcomesѻý> Randomized trial supports combined surgery for moderate regurgitation Nov 13, 2021
<ѻý>Delaying Surgery Hurts Patients With Silent Aortic Stenosisѻý> Early aortic valve replacement wins in AVATAR trial Nov 13, 2021
<ѻý>Pulmonary Pressure Monitoring Helps HFpEF Tooѻý> GUIDE-HF substudy supports similar benefits across the ejection fraction spectrum Nov 07, 2021
<ѻý>More Good News for Empagliflozin in Patients With Heart Failureѻý> Slower renal function decline with SGLT-2 inhibitor in EMPEROR-Preserved trial Nov 06, 2021
<ѻý>Longstanding Vascular Closure Technique Triumphs Over Collagen Plugѻý> Manta versus ProGlide after transfemoral TAVR in CHOICE-CLOSURE Nov 06, 2021
<ѻý>TAVR Operators Divided on Need for Bicuspid RCTѻý> Odds of a study coming to fruition are low Nov 05, 2021
<ѻý>Too Many TAVR Centers Are Clustered Around Well-to-Do Communitiesѻý> More centers not the answer to geographic, socioeconomic disparities in access? Oct 22, 2021
<ѻý>Study: Kids Exposed to Harmful Plastics During Heart Surgeryѻý> Are tubing and blood bags sources of trouble? Oct 09, 2021
<ѻý>Post-TAVR Pacemakers Not All Doom and Gloomѻý> A bit of reassurance from Swedish cohort study Oct 04, 2021
<ѻý>Low Risk and Bicuspid Anatomy: A Passable Combination for TAVR Thus Farѻý> Clinical outcomes not worse compared with tricuspid TAVR Sep 21, 2021
<ѻý>With HVAD Out, Innovation Key to Mechanical Circulatory Supportѻý> A debate on where LVAD innovation stands Sep 14, 2021
<ѻý>Transplant Docs Are Sticking With Invasive Biopsies After Heart Transplantsѻý> Agreement that non-invasive alternatives to EMB are not ready for routine rejection surveillance Sep 13, 2021
<ѻý>SGLT2 Inhibitor Eases Symptoms for HFpEF Patientsѻý> Trial suggests hard outcomes not the only ones helped by this class of medication Sep 13, 2021
<ѻý>Second-Gen Drug for HCM Emerges, Nipping at Mavacamten's Heelsѻý> Novel cardiac myosin inhibitor is headed for a phase III trial Sep 12, 2021
<ѻý>Heart Failure's 'Golden Moment' Not Translating into Better Healthѻý> Problems of implementation and health equity persist Sep 12, 2021
<ѻý>Feared ARNI Effect on Cognition Hasn't Come to Fruitionѻý> Neurocognitive protection by sacubitril/valsartan suggested instead by observational study Sep 12, 2021
<ѻý>Some Reassurance on Cognition in People With Older LVADsѻý> Will newer devices look even better for neurological outcomes? Sep 08, 2021
<ѻý>Good Results When Giving Flu Shots to MI Survivors Still in the Hospitalѻý> Vaccination prior to discharge linked to heart benefit Aug 30, 2021
<ѻý>Polypills Ready for Prime Time in Large Swaths of People, Researchers Sayѻý> Question now is how to implement fixed-dose combo therapy in clinical practice Aug 29, 2021
<ѻý>His Bundle Pacing Stars in European Guidelinesѻý> Revised edition could signal coming U.S. recommendations too Aug 29, 2021
<ѻý>Ablation, CRT Boost Survival in Permanent Afib With Narrow QRSѻý> APAF-CRT trial reinforces the case for expanded CRT indication Aug 28, 2021
<ѻý>Revamped Valve Disease Guideline: Europe Sees Nearly Eye to Eye With U.S.ѻý> There is a different approach to deciding the suitability of TAVR, however Aug 28, 2021
<ѻý>A Familiar Drug Can Keep Early-Stage HCM at Bayѻý> Treatment with valsartan most beneficial when started early? Aug 27, 2021
<ѻý>Empagliflozin Improves Outcomes in HFpEF Patientsѻý> "A major win" for heart failure with preserved ejection fraction, says editorialist Aug 27, 2021
<ѻý>New Heart Failure Guidelines Released, but Are They Already Out of Date?ѻý> Results of EMPEROR-Preserved contradict guidance Aug 27, 2021
<ѻý>Milder Heart Failure Might Benefit From Implantable Monitorsѻý> Randomized trial signals benefit, albeit hampered by the pandemic Aug 27, 2021
<ѻý>Deadly Arrhythmias Less of a Risk for HF Patients on Dapagliflozinѻý> DAPA-HF analysis further explores mechanism of SGLT2 inhibitor's heart benefits Aug 27, 2021
<ѻý>Heart Failure Again Takes Center Stage at ESCѻý> EMPEROR-Preserved, new guidelines, and more to come Aug 26, 2021
<ѻý>Inotrope Showdown Leaves No Winner in Cardiogenic Shockѻý> Long-awaited head-to-head comparison of milrinone and dobutamine Aug 04, 2021
<ѻý>TAVR Debris Deflector Doesn't Fly With FDA Advisory Panelѻý> TriGuard 3 met with skepticism in its bid for approval Aug 04, 2021
<ѻý>Start Rhythm Control Early for Afib With Heart Failureѻý> EAST-AFNET 4 trial finds similar benefits across ejection fraction ranges Jul 31, 2021
<ѻý>SGLT2 Inhibitor Adds Years of Life to Patients With Heart Failureѻý> DAPA-HF group makes projections as long-term data are lacking Jul 28, 2021
<ѻý>Changes in Epicardial Fat May Drive SGLT2 Inhibitor Benefitsѻý> More insight into mechanisms behind empagliflozin's cardioprotection Jul 26, 2021
<ѻý>Surprising Tradeoffs of Valve-in-Valve TAVR vs Redo Surgeryѻý> Observational study suggests excess readmissions with less invasive procedure Jul 23, 2021
<ѻý>Does COAPT Change the Need to Try Foundational HF Drugs in Functional MR?ѻý> Current GDMT titration approach under fire during TVT debate Jul 21, 2021
<ѻý>After Some Early Successes for Bicuspid TAVR, a Randomized Trial May Be Unlikelyѻý> Are observational data on highly selected patients good enough? Jul 21, 2021